Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Dose-response study of S42909 for venous leg ulcer healing
2016-004143-36Phase 2Completed
- Sponsor
- Ilkos Therapeutics
- Start
- Apr 2017
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised trial of ilkodostat in stasis ulcer (3 arms), sponsored by Ilkos Therapeutics. Primary endpoint: Relative reduction of reference ulcer area at 4 weeks. Started Apr 2017; status: completed.
02
Drugs
ilkodostat
03
Conditions
stasis ulcer
Beyond the preview
Go deeper on 2016-004143-36.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2016-004143-36.